GlassScriptPhysician profile
Farida Bounoua
NPI 1992925564
$23,720.28
in general payments reported to CMS, 2019-2025
18 companies · $213 in 2025
The $213 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $107 · 2021: $15K · 2022: $3,240 · 2023: $3,971 · 2024: $347 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,154 · Food and Beverage: $1,342 · Travel and Lodging: $36.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,154.05 |
| Food and Beverage | $1,341.81 |
| Travel and Lodging | $36.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $20,944.39 | 2021-2024 | Davinci Xi, Da Vinci Surgical System, Da Vinci Sp |
| Medtronic, INC. | $1,353.71 | 2021-2024 | Signia, Endo Gia Ultra, Eea |
| Covidien LP | $510.20 | 2019-2020 | |
| Tela Bio, INC. | $136.12 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Ethicon US, LLC | $110.77 | 2021-2022 | |
| Ambu INC. | $104.79 | 2024 | |
| Heron Therapeutics, INC. | $90.76 | 2022 | |
| Allergan, INC. | $82.49 | 2022 | |
| Boston Scientific Corporation | $78.83 | 2021 | |
| Karl Storz Endoscopy-America | $61.59 | 2022 | |
| Novo Nordisk INC | $45.36 | 2025 | Ozempic |
| Smith+Nephew, INC. | $41.76 | 2024 | Stravix |
| Olympus America INC. | $34.59 | 2022 | |
| Davol INC. | $33.16 | 2019 | |
| Acell, INC. | $32.79 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $31.66 | 2025 | Zepbound |
| Cook Medical LLC | $14.80 | 2019 | |
| Omeros Corporation | $12.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farida Bounoua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.